健倍苗苗(02161.HK)預計年度股東應佔綜合溢利同比增長不少於50% 核心品牌錄得強勁銷售表現
格隆匯5月19日丨健倍苗苗(02161.HK)公佈,集團預期截至2025年3月31日止年度的股東應佔綜合溢利將較截至2024年3月31日止年度增加不少於50%。
綜合溢利大幅增長,主要歸因於精準品牌管理推廣活動,成功帶動集團核心品牌錄得強勁銷售表現,尤其是品牌藥分部的何濟公以及品牌中藥分部的保濟丸及飛鷹活絡油。此斐然成績凸顯集團的線下及線上渠道銷售及營銷策略之有效執行能力,亦反映集團具前瞻性的策略眼光,成功把握品牌消費保健產品於香港、澳門及大灣區內重點城市的增長潛力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.